Cargando…

Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis

OBJECTIVE: The objective of this study was to compare platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose-derived mesenchymal stem cell (MSC) injections in the treatment of osteoarthritis (OA) of the knee using functional scores. METHODS: A total of 89 patients with pain...

Descripción completa

Detalles Bibliográficos
Autores principales: Estrada, Esteban, Décima, Jose L, Rodríguez, Marcelo, Di Tomaso, Marianela, Roberti, Javier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336820/
https://www.ncbi.nlm.nih.gov/pubmed/32669883
http://dx.doi.org/10.1177/1179544120931086
_version_ 1783554398684708864
author Estrada, Esteban
Décima, Jose L
Rodríguez, Marcelo
Di Tomaso, Marianela
Roberti, Javier
author_facet Estrada, Esteban
Décima, Jose L
Rodríguez, Marcelo
Di Tomaso, Marianela
Roberti, Javier
author_sort Estrada, Esteban
collection PubMed
description OBJECTIVE: The objective of this study was to compare platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose-derived mesenchymal stem cell (MSC) injections in the treatment of osteoarthritis (OA) of the knee using functional scores. METHODS: A total of 89 patients with painful knee OA were included in this study. Patients were assigned to one of the 3 treatments according to severity of OA as indicated by symptoms and radiography to PRP (stage I), BMAC (stage II), or adipose-derived MSC (stage III). Clinical assessment was performed using the Knee Society Score, which combines the Knee Score, based on the clinical parameters, and the Functional Score, and IKDC score. Surveys were completed at preoperative and at 90, 180, and 265 days postoperative. The follow-up responses were compared with baseline and between treatment groups. RESULTS: Treatment with PRP, BMAC, and adipose-derived MSC included 29 (32.6%), 27 (30.3%), and 33 (37.1%) patients, respectively. For the total group, median age was 61 years (range: 22-84 years). Score values were comparable among treatment groups at baseline. Statistically significant improvement was observed in the 3 groups according to the 3 scores at all time points during follow-up compared with baseline. No difference was found among treatment type. CONCLUSIONS: Our findings support previous reports and encourage further research on the use of these cost-effective treatments for OA of the knee.
format Online
Article
Text
id pubmed-7336820
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-73368202020-07-14 Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis Estrada, Esteban Décima, Jose L Rodríguez, Marcelo Di Tomaso, Marianela Roberti, Javier Clin Med Insights Arthritis Musculoskelet Disord Original Research OBJECTIVE: The objective of this study was to compare platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and adipose-derived mesenchymal stem cell (MSC) injections in the treatment of osteoarthritis (OA) of the knee using functional scores. METHODS: A total of 89 patients with painful knee OA were included in this study. Patients were assigned to one of the 3 treatments according to severity of OA as indicated by symptoms and radiography to PRP (stage I), BMAC (stage II), or adipose-derived MSC (stage III). Clinical assessment was performed using the Knee Society Score, which combines the Knee Score, based on the clinical parameters, and the Functional Score, and IKDC score. Surveys were completed at preoperative and at 90, 180, and 265 days postoperative. The follow-up responses were compared with baseline and between treatment groups. RESULTS: Treatment with PRP, BMAC, and adipose-derived MSC included 29 (32.6%), 27 (30.3%), and 33 (37.1%) patients, respectively. For the total group, median age was 61 years (range: 22-84 years). Score values were comparable among treatment groups at baseline. Statistically significant improvement was observed in the 3 groups according to the 3 scores at all time points during follow-up compared with baseline. No difference was found among treatment type. CONCLUSIONS: Our findings support previous reports and encourage further research on the use of these cost-effective treatments for OA of the knee. SAGE Publications 2020-07-03 /pmc/articles/PMC7336820/ /pubmed/32669883 http://dx.doi.org/10.1177/1179544120931086 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Estrada, Esteban
Décima, Jose L
Rodríguez, Marcelo
Di Tomaso, Marianela
Roberti, Javier
Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis
title Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis
title_full Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis
title_fullStr Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis
title_full_unstemmed Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis
title_short Patient-Reported Outcomes After Platelet-Rich Plasma, Bone Marrow Aspirate, and Adipose-Derived Mesenchymal Stem Cell Injections for Symptomatic Knee Osteoarthritis
title_sort patient-reported outcomes after platelet-rich plasma, bone marrow aspirate, and adipose-derived mesenchymal stem cell injections for symptomatic knee osteoarthritis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7336820/
https://www.ncbi.nlm.nih.gov/pubmed/32669883
http://dx.doi.org/10.1177/1179544120931086
work_keys_str_mv AT estradaesteban patientreportedoutcomesafterplateletrichplasmabonemarrowaspirateandadiposederivedmesenchymalstemcellinjectionsforsymptomatickneeosteoarthritis
AT decimajosel patientreportedoutcomesafterplateletrichplasmabonemarrowaspirateandadiposederivedmesenchymalstemcellinjectionsforsymptomatickneeosteoarthritis
AT rodriguezmarcelo patientreportedoutcomesafterplateletrichplasmabonemarrowaspirateandadiposederivedmesenchymalstemcellinjectionsforsymptomatickneeosteoarthritis
AT ditomasomarianela patientreportedoutcomesafterplateletrichplasmabonemarrowaspirateandadiposederivedmesenchymalstemcellinjectionsforsymptomatickneeosteoarthritis
AT robertijavier patientreportedoutcomesafterplateletrichplasmabonemarrowaspirateandadiposederivedmesenchymalstemcellinjectionsforsymptomatickneeosteoarthritis